The conundrum of C-reactive protein as a risk marker for cardiovascular risk assessment: Insight from EPIC-Norfolk and JUPITER

European Heart Journal

Volumn 34, Issue 18, 2013, Pages 1318-1320

  Chapman, M John ^a   Giral, Philippe ^a   Barter, Philip J ^b  

^a INSERM   (France)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG QUALITY; DYSLIPIDEMIA; EDITORIAL; HEALTH CARE COST; HEREDITY; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 84877751672     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht074     Document Type: Editorial

References (11)

1. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818
2. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-329
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511
4. Sondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJP, Wareham NJ, Khaw K-T. Clinical implications of JUPITER in a contemporary European population: The EPIC-Norfolk prospective population study. Eur Heart J 2013;34:1350-1357
5. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: The EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-422
6. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, Sandhu MS, Jukema JW, Kastelein JJ, Hack CE, Khaw KT. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25:839-846
7. Rana JS, Boekholdt SM, Ridker PM, Jukema JW, Luben R, Bingham SA, Day NE, Wareham NJ, Kastelein JJ, Khaw KT. Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: The EPIC-Norfolk Prospective Population Study. J Intern Med 2007;262:678-689
8. Rana JS, Cote M, Després JP, Sandhu MS, Talmud PJ, Ninio E, Wareham NJ, Kastelein JJ, Zwinderman AH, Khaw KT, Boekholdt SM. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: The EPIC-Norfolk prospective population study. Heart 2009;95:1682-1687
9. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
10. Wang TJ. Multiple biomarkers for predicting cardiovascular events: Lessons learned. J Am Coll Cardiol 2010;55:2092-2095
11. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet 2009;373: 1175-1182